Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dendritic Cell–Specific Intercellular Adhesion Molecule-3-Grabbing Nonintegrin (DC-SIGN)
- Target
- DC-SIGN
- Molecular classification
- C-type lectin superfamily, Type II transmembrane glycoprotein, Receptor
01
Overview
DC-SIGN/CD209 is a multifunctional pattern recognition receptor central to both innate immunity—through direct pathogen binding—and adaptive immunity via antigen presentation. Its dual roles make it both a facilitator of host defense mechanisms and a potential vulnerability exploited by diverse pathogens.
- Other names
- CD209
02
Mechanism of action
Targeting antigens to DC-SIGN can enhance vaccine efficacy by improving antigen delivery/presentation. Blockade or modulation of DC-SIGN may also have therapeutic potential against infections where the receptor facilitates pathogen entry or immune evasion.
03
Biological functions
Antigen uptakeAntigen presentationCell adhesionCell migrationImmune regulationPattern recognitionSignaling modulation
04
Disease associations
InfectionHIV/AIDSHepatitis CAutoimmune conditionsCancer
05
Safety considerations
Pathogen exploitation for immune evasionPotential for immunosuppression/tolerance induction
Beyond the preview
Go deeper on Dendritic Cell–Specific Intercellular Adhesion Molecule-3-Grabbing Nonintegrin (DC-SIGN).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dendritic Cell–Specific Intercellular Adhesion Molecule-3-Grabbing Nonintegrin (DC-SIGN).